Therkildsen, J. http://orcid.org/0000-0003-4027-4631
Rohde, P.D.
Nissen, L.
Thygesen, J.
Hauge, E.-M.
Langdahl, B.L.
Boettcher, M.
Nyegaard, M.
Winther, S.
Funding for this research was provided by:
Aarhus University Hospital
Article History
Received: 11 January 2023
Accepted: 10 July 2023
First Online: 26 July 2023
Declarations
:
: All individual participants gave written, informed consent before enrolment in the study. The Central Denmark Regional Committee on Health Research Ethics (date: 2014-07-30, ref.: 1-10-72-190-14) and the Danish Data Protection Agency (ref.: 1-16-02-345-14) approved this study. The trial was registered at ExternalRef removed (NCT02264717). All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Ellen-Margrethe Hauge has received honorariums and/or consulting fees from AbbVie, Sanofi, Sobi, and SynACT Pharma and research grants to Aarhus University Hospital from Danish Regions Medicine Grants, Danish Rheumatism Association, Roche, Novartis, and Novo Nordic Foundation. Bente L. Langdahl has received honorariums from Amgen, UCB, Gedeon-Richter, Astra-Zenica, and Astellas and worked as a consultant for Amgen, UCB, Gedeon-Richter, and Gilead. Furthermore, Bente L. Langdahl has received financial grants from Amgen and the Novo Nordic Foundation. Morten Boettcher disclosed advisory board participation for NOVO Nordisk, Astra-Zeneca, Pfizer, Boeringer Ingelheim, Bayer, Sanofi, Novartis, and Acarix. Josephine Therkildsen, Palle Duun Rohde, Louise Nissen, Jesper Thygesen, Mette Nyegaard, and Simon Winther declare no competing interests.